Paraquat Lawsuit Updates, Settlement and Eligibility (2026)
Read in 13mins
Litigation Active – Paraquat Cases Are Still Pending
Status: Active – global settlement in progress, cases that declined offers moving through discovery
Docket: MDL No. 3004 – In re: Paraquat Products Liability Litigation
Court: U.S. District Court for the Southern District of Illinois – Chief Judge Nancy J. Rosenstengel
Pending cases: 6,635 (JPML, as of November 2, 2026)
Next key date: No trial date set
Article Summary
- Paraquat is a restricted agricultural chemical used for weed control
- It can cause life-threatening illnesses
- If you’ve been harmed by Paraquat, reach out to a lawyer as soon as you can
Paraquat is a highly toxic chemical that has been used as an herbicide on commercial farms since the 1960s. It is an active ingredient in Blanco, Firestorm, Devour and many other agricultural-grade herbicides.
Because of the health risks associated with Paraquat (most commonly Parkinson’s Disease), it is banned in dozens of countries. It may still be used in the U.S. with a valid license. However, California canceled all Paraquat product licenses in August 2026, and Syngenta announced it would cease manufacture by late June 2026.
A federal Paraquat multidistrict litigation (MDL) had 6,635 pending cases as of November 2, 2026. In April 2025, the lead lawyers on both sides reached a tentative global settlement. Plaintiffs can decline their offers, but they must prove their claims in court to recover injury compensation.
Today, additional cases are pending in a Philadelphia mass tort program. Although these cases are pending in Pennsylvania state court, they have been filed by plaintiffs across the country. Here’s what to know about the latest Paraquat updates.
Free Paraquat Lawsuit Case Review!
Mentioned by
- Major Developments in the Lawsuit History
- What Is the Paraquat Lawsuit?
- Latest Updates on the Paraquat MDL
- Past Paraquat Lawsuit Updates
- What Is Paraquat?
- Who Manufactures Paraquat and Where Is It Used?
- Symptoms and Health Risks of Paraquat Exposure
- How to Qualify for a Paraquat Lawsuit
- Paraquat Lawsuit Settlements & Payouts
- How Much Can You Get From the Paraquat Lawsuit?
- Legal and Financial Options for Paraquat Victims
- Factors That Determine Paraquat Settlement Amounts
- Proving Paraquat Exposure and Building a Case
Major Developments in the Lawsuit History
- October 15, 2026: Under Case Management Order No. 27, Smith Law Firm clients who turned down their offers had until Oct. 28, 2026, to hand over fact sheets and all medical records.
- July 27, 2026: After the Supreme Court's Monsanto v. Durnell decision, Syngenta and Chevron renewed their request to throw out label-based warning claims as blocked by federal pesticide law.
- May 9, 2025: The court paused test trial deadlines after lead lawyers on both sides reached a tentative deal to settle the litigation.
- April 17, 2024: The judge barred the plaintiffs' only expert on whether paraquat can cause Parkinson's and dismissed the first four trial cases.
- June 7, 2021: A federal panel combined paraquat Parkinson's lawsuits into MDL No. 3004 in the Southern District of Illinois.
Following the case
64 updatesFull Paraquat Lawsuit Updates Timeline (2021–2026)
Court Sets Firm Deadlines for Smith Firm Holdouts
A day after denying a request to pause CMOs 25 and 26, Judge Rosenstengel entered Case Management Order No. 27. Smith Law Firm clients who turned down their offers had until Oct. 28, 2026, to serve verified fact sheets and all medical records, and had to be made available for depositions by Feb. 16, 2027. The firm was told to disclose, for private court review, every person or company with a financial stake in those cases, including litigation funders. In-person status conferences every two weeks were set to begin Nov. 5, 2026.
Smith Firm Opt-Outs Given 30 Days to Produce Evidence
Case Management Order No. 26 applied to Smith Law Firm plaintiffs who declined their settlement offers. It gave them 30 days to serve the evidence package required by CMO 25, such as fact sheets, records of paraquat use, and witness affidavits. Case-specific expert reports were due within 60 days.
Judge Questions DiCello Firm Over Opt-Outs
After reviewing early discovery in the firm's declined cases, the court ordered attorney Mark DiCello to appear by video. At the Aug. 27 hearing, he was told to work through the cases of concern with Special Master Randi Ellis. On Sept. 11, the judge canceled the follow-up hearing after Ellis reported real progress, and asked her to keep sending updates.
Show 61 earlier updates
All Paraquat Products Canceled in California
California's Department of Pesticide Regulation announced the cancellations after every maker of paraquat-dichloride products voluntarily gave up its state registration, the last on Aug. 6, 2026. The state had opened a reevaluation in November 2024 that called for new safety data by June 5, 2026. Licensed dealers may still possess and sell canceled products for up to two years after each cancellation takes effect.
Philadelphia Plaintiffs' Leadership Order Vacated
Judge Joshua Roberts vacated CMO 26, a Philadelphia case management order, and the part of an earlier order that had appointed plaintiffs' liaison counsel, lead counsel, and an executive committee for the Philadelphia paraquat program (docket 220500559). The same order also vacated Case Management Order No. 6.
Defendants Renew Preemption Motion After Durnell
Following the Supreme Court's June 25, 2026 decision for Monsanto in Monsanto v. Durnell, Syngenta and Chevron filed a supplemental motion in the MDL. They asked the court to end label-based failure-to-warn claims as preempted, meaning overridden, by federal pesticide law. Plaintiffs filed their opposition on Aug. 26, and the defendants replied on Sept. 9, 2026.
Renewed Venue Motions Denied in Philadelphia
Syngenta and Chevron filed new interstate forum non conveniens motions in Philadelphia on June 1, 2026. On July 13, Judge Roberts denied the motion to dismiss and closed the related motions under that ruling. He also approved stipulations between the defendants and the plaintiffs in 16 named cases about those motions; the docket text does not give their terms.
Appeal of First Bellwether Dismissals Stays on Hold
The Seventh Circuit kept the appeal paused in Nos. 24-1865 to 24-1868, which challenge the 2024 dismissal of the first four MDL bellwether cases, while the parties finalized an agreement to resolve it. In August, the appeals court granted another extension and set Sept. 11, 2026, for a status report or a motion to drop the appeal.
Trial Judge Files Opinion in Venue Appeal
Judge Roberts filed his opinion for the Superior Court in appeal No. 154 EDA 2026, the defendants' challenge to his July 2025 forum ruling, and it was sent to that court electronically. On Oct. 8, 2026, he ordered the full Philadelphia global docket sent up as a supplemental certified record.
CMO 25 Lists Proof Required From Non-Settling Plaintiffs
Case Management Order No. 25 covers plaintiffs who reject or do not qualify for the global deal, plus anyone filing later. Those who decline an offer had 30 days to contact Special Master Randi Ellis and set up a personal meeting. Each must also serve a sworn fact sheet, proof of paraquat use, witness affidavits, a Parkinson's diagnosis from a movement disorder specialist or neurologist made at least 10 years after first use, and a case-specific causation expert report. Deadlines were left for a later order, and failure to comply can mean dismissal with prejudice.
Third Firm's Declined Cases Picked for Discovery
The court selected a random sample of Nachawati Law Group cases for limited discovery after learning that 183 of the firm's 217 settlement-eligible clients had refused their offers. The chosen plaintiffs faced the same fact sheet, deposition, and narrow records discovery ordered a day earlier for two other firms.
Court Probes High Opt-Out Rates at Two Firms
Judge Rosenstengel noted that every DiCello Levitt client and more than 90% of Smith Law Firm clients had declined their settlement offers. To learn why, she randomly picked about 10% of each firm's declined cases to undergo limited discovery. Selected plaintiffs had 14 days to complete fact sheets and 60 days to be deposed, and defendants could subpoena retailers or supervisors where proof of paraquat use was missing.
Special Master Gets Settlement Data on Holdouts
Case Management Order No. 24 required plaintiffs' settlement administrators to give Special Master Randi Ellis, by April 20, 2026, the names of claimants found ineligible, those opting out, and those still undecided, along with each tier, offer amount, and the information behind it. Ellis was then to meet with plaintiffs who had not accepted, so their choice would be informed, and to report to the court within 90 days.
Preemption Motion Put on Hold for Supreme Court
The Supreme Court had agreed to decide in Monsanto v. Durnell whether federal pesticide law bars label-based failure-to-warn claims. Both sides agreed that ruling could affect the paraquat claims, so the MDL court put the motion on hold. Defendants were given 30 days after the decision to supplement or withdraw it.
April 2026 MDL Trial Canceled
Citing the pending settlement, the court canceled the trial set for April 6, 2026. That date had been chosen in January 2025 for the Phase 2 bellwether cases of Peek, Okerlund, and Malish.
Syngenta Says It Will Stop Making Paraquat
Syngenta announced it would cease making paraquat worldwide, with output ending by late June 2026. The company said generic competition had eroded its position and that it would phase out output at its Huddersfield, U.K., site, its only plant making the active ingredient.
Court Approves Paraquat Settlement Fund
Granting a joint request, the court ordered the creation of a qualified settlement fund, a court-supervised account that holds settlement money before it is paid out. The judge kept continuing jurisdiction over the fund.
Defendants Argue Warning Claims Are Preempted
Syngenta and Chevron filed a joint motion for partial summary judgment, a ruling without trial, against all failure-to-warn claims in the MDL. They argued that FIFRA, the federal pesticide law, preempts them because EPA approves paraquat labels and would not have allowed a Parkinson's warning. Days later, CMO 23 said plaintiffs could drop cases only by joint stipulation or court order.
Mertens Evidence Rulings Applied Program-Wide
A second deeming order made the motions in limine, which are requests to allow or bar evidence at trial, and the court's rulings on them in Mertens v. Syngenta Crop Protection (No. 220200931) count as filed and decided in every Philadelphia paraquat case. Parties had to tell each expected trial witness about those rulings.
Superior Court Agrees to Hear Venue Appeal
The Pennsylvania Superior Court granted the defendants permission to appeal the July 11, 2025 order that refused to dismiss Philadelphia paraquat cases on interstate forum non conveniens grounds (No. 179 EDM 2025). The appeal went forward as No. 154 EDA 2026.
Settlement Stay Extended to March 2026
The court extended the stay of bellwether discovery deadlines to March 6, 2026, so the settlement process could continue, and canceled the Jan. 5, 2026 status conference. Individual plaintiffs still had to meet their questionnaire and subpoena duties under earlier orders.
EPA Asks Makers for More Paraquat Vapor Data
EPA released an updated review finding more uncertainty than before about whether paraquat can volatilize, or turn into vapor, and move off treated fields. The review followed a January 2024 Syngenta vapor pressure study. EPA said manufacturers would receive a data call-in notice and that it would finish endangered species and endocrine reviews before any final registration decision.
Monthly Philadelphia Trials Planned Through July 2027
Case Management Order No. 21 in the Philadelphia program kept bellwether trials set for January and April 2026 on the calendar. It added one trial slot each month from August 2026 through July 2027, drawn from 120 cases to be readied for trial, with exact jury selection and trial dates left for a later order.
Supreme Court Turns Away Syngenta Petition
The U.S. Supreme Court declined to hear Syngenta Crop Protections v. Nemeth, No. 24-1190, a Philadelphia paraquat case. Syngenta filed the petition in May 2025 after the Pennsylvania Supreme Court refused to hear its appeal from a Superior Court ruling.
Judge Summons Attorney Over Settlement Video Call
The court ordered attorney Aimee Wagstaff to explain a planned video call for other plaintiffs' lawyers, voicing concern that she might be urging clients she did not represent to reject the global deal before its details were known. Wagstaff, who had left the plaintiffs' executive committee at her request, appeared on Oct. 14, 2025, and was directed to confer with Special Master Ellis.
October 2025 Bellwether Trial Vacated
The court vacated the October trial set for Oct. 14, 2025, and extended the stay of bellwether discovery deadlines to Jan. 5, 2026, to let the settlement process unfold. The order reminded plaintiffs that their obligations under CMOs 10, 21, and 21A still applied.
FMC Dropped From Many Philadelphia Cases
The Philadelphia court granted FMC Corporation's motion to discontinue all claims against it in a list of paraquat cases. Similar orders covering other attached case lists followed on Oct. 15, 2025, Jan. 22, 2026, Feb. 25, 2026, and April 9, 2026.
Discovery Pause Extended to Late September
For a third time, the court extended the pause on bellwether discovery deadlines, this time to Sept. 26, 2025, so lead counsel could keep working to finalize the settlement terms.
Nemeth Rulings Extended to All Philadelphia Cases
A deeming order made the motions and the court's rulings in Nemeth v. Syngenta Crop Protection (No. 210800533) count as filed and decided in every case in the Philadelphia paraquat program. Parties had to tell each expected trial witness what those rulings said.
Philadelphia Judge Refuses to Dismiss on Venue Grounds
Judge Roberts denied the defendants' motion to dismiss Philadelphia paraquat cases under interstate forum non conveniens, a doctrine that lets a court send a case to a more suitable state. On Aug. 11, 2025, he also refused to certify the ruling for an immediate appeal.
Settlement Stay Extended to July 21
The court extended the stay of bellwether discovery deadlines to July 21, 2025, giving lead counsel more time to finish a settlement agreement. Individual plaintiffs' duties under CMOs 10, 21, and 21A were not affected.
Bellwether Deadlines Paused After Tentative Deal
The court stayed bellwether discovery deadlines for 30 days after learning on April 14, 2025, that lead counsel for both sides had reached a tentative agreement to settle the litigation. The parties had to report on a final agreement by June 11, 2025.
Appeals Court Refuses to Send Paraquat Review Back to EPA
A coalition of farmworker and health groups, with Michael J. Fox's Parkinson's foundation among them, had challenged EPA's paraquat decision in the Ninth Circuit (No. 21-71287). In January 2025, EPA asked for a voluntary remand, meaning a chance to reconsider the decision on its own. The court denied that request and instead granted Syngenta's motion to put the case on hold, with EPA filing status reports every 90 days until its reconsideration ends.
Pennsylvania Supreme Court Rejects Syngenta Appeal
The Pennsylvania Supreme Court turned down Syngenta's request for permission to appeal in a Philadelphia paraquat case brought by Douglas Nemeth, No. 289 EAL 2024. It also turned down Syngenta's request for a stay while the petition was pending.
Six New Bellwether Cases Get Trial Dates
After a December 2024 status conference, the court ordered full discovery in six cases split into two phases. Phase 1 (Tucker, Scibilia, and Bork) was set for a first trial on Oct. 14, 2025, and Phase 2 (Peek, Okerlund, and Malish) for a first trial on April 6, 2026. Summary judgment and Daubert briefs were due Aug. 15, 2025, and Feb. 13, 2026.
Plaintiffs' Leadership Team Reappointed
In Case Management Order No. 22, the court renewed the appointments of plaintiffs' co-lead counsel, MDL and state court liaison counsel, and the executive committee that coordinate the case for all plaintiffs. The roles stayed personal and could be changed or expanded if needed.
Court Enforces Exposure Subpoena Rule
Defendants had identified 586 plaintiffs who allegedly never sent the third-party subpoenas CMO 21 required. Case Management Order No. 21A gave some of them 21 days to comply and let defendants list holdouts after Nov. 27, 2024, for possible dismissal without prejudice. Future filers must issue subpoenas within 60 days of filing.
Ten New Cases Chosen After First Pool Fails
Replacing the dismissed trial pool, the court selected ten cases for case-specific discovery. Depositions were due by Nov. 25, 2024, and one-page case summaries by Dec. 16, 2024, after which a smaller group would be chosen for full trial preparation.
First Four Philadelphia Trials Scheduled
Case Management Order No. 10 set trial dates for the first four bellwether trials in the Philadelphia paraquat program (docket 220500559). Later orders in January and May 2025 changed the pretrial deadlines for those trials.
Randi Ellis Named Philadelphia Mediator
In Case Management Order No. 9, the Philadelphia court appointed Randi Ellis, already the federal MDL's special master, as discovery and settlement mediator for all matters in its paraquat mass tort program.
Causation Expert Excluded and Bellwethers Dismissed
The court excluded the testimony of Dr. Martin Wells, the plaintiffs' only general causation expert (on whether paraquat can cause Parkinson's at all), under Federal Rule of Evidence 702. Without him, the four trial cases (Richter, Fuller, Burgener, and Coward) were dismissed the same day. The parties were told to propose 16 new cases by May 10, 2024.
Plaintiffs Told to Subpoena Proof of Exposure
Case Management Order No. 21 directed every MDL plaintiff to serve third-party subpoenas for documents proving paraquat use or exposure and to upload any such records to the questionnaire portal. The court said the step would help plaintiffs gauge their claims and expose meritless ones.
Philadelphia Judge Rejects Pleading Challenges
Judge Joshua Roberts overruled the preliminary objections that the defendants raised, a Pennsylvania procedure similar to a motion to dismiss, against the plaintiffs' long-form complaint in docket 220500559. The same day, he granted a plaintiffs' motion to strike and lifted every earlier discovery stay in the Philadelphia paraquat cases.
Discovery Ordered in 25 Questioned Cases
Concerned that many of the more than 5,000 plaintiffs did not plausibly allege paraquat exposure, the court chose 25 plaintiffs for depositions and narrow records discovery, to be completed by March 22, 2024. It warned it could impose costs and fees if a suit had no good-faith basis.
Syngenta Loses Bid for Researcher's Files
The court refused to force Dr. Earl Ray Dorsey to give Syngenta disputed documents about an article he wrote on paraquat and granted his motion to quash those requests. The judge found the files were of marginal value to the scientific debate and that the burden of producing them outweighed that value.
Philadelphia Sets Bellwether Selection Process
Case Management Order No. 5 set how the first round of Philadelphia bellwether, or test, trial cases would be chosen, starting from the first 57 cases filed. Judge Joshua Roberts issued an amended version on Nov. 30, 2023, after granting the defendants' request for reconsideration.
Expert Hearing Ends and Fall 2023 Trial Dropped
A four-day hearing on challenges to both sides' experts, known as Daubert motions, ended on Aug. 24, 2023, with arguments about four more experts. Closing briefs were due Sept. 8, 2023, and they had to address how a Seventh Circuit precedent applied to Dr. Wells. Because of that schedule, the October 2023 trial setting was called off.
Philadelphia Court Keeps Jurisdiction Over Syngenta's U.S. Unit
Judge Abbe Fletman ruled on the jurisdiction objections in the Philadelphia program. She found the court lacked general jurisdiction over Syngenta AG, but kept Syngenta Crop Protection LLC in the cases because it had registered in Pennsylvania as a foreign company, relying on the U.S. Supreme Court's ruling in Mallory v. Norfolk Southern Railway Co. On Nov. 2, 2023, she refused to certify that ruling for an immediate appeal.
Nuisance Claim Dropped in One Trial Case
Ruling on a supplemental defense motion, the court dismissed the public nuisance count in Fuller, one of the four trial selection cases. It denied the motion without prejudice for all other public nuisance claims, pending further talks among the parties and the court.
Court Moves to Clean Up the MDL Docket
After defense claims that some suits and sworn questionnaires were filed for people who had already died, the court voiced concern about the integrity of its docket in Case Management Order No. 18. It told both sides to meet and discuss suits resting on implausible theories, such as no known paraquat exposure or no medical proof of Parkinson's, with any defense motion due by June 20, 2023.
First Trial Moved to October 2023
Case Management Order No. 16 reset expert and motion deadlines, canceled the July and September 2023 trial dates, and set the first bellwether trial for Oct. 16, 2023. The judge pointed to hurricanes, illnesses, family emergencies, and resistance to coordinating with state court litigation.
First Trial Pushed to July 2023
Case Management Order No. 15 canceled the November 2022, March 2023, and June 2023 trial settings and moved the first bellwether trial to July 24, 2023. Summary judgment and Daubert motions were due March 8, 2023.
Philadelphia Creates Paraquat Mass Tort Program
A judge of Philadelphia's Court of Common Pleas granted mass tort designation for the paraquat cases pending in that court. All of them moved to the Complex Litigation Center and were coordinated under one master docket, No. 220500559, with defendants' response deadlines paused until a first case management order.
Six Cases Chosen for Full Trial Preparation
After reviewing confidential rankings from both sides, the court chose six of the 16 early cases for full fact and expert discovery. Four of them, Richter, Fuller, Burgener, and Coward, later became the MDL's first trial selection cases.
Some Claims Against Syngenta and Chevron Dismissed
Ruling on partial motions to dismiss, the court granted them in part. It threw out the public nuisance counts Chevron challenged in the listed cases, plus Minnesota consumer protection claims against Syngenta brought by plaintiffs with no Minnesota connection. The remaining parts of both motions were denied.
Pool of 16 Early Trial Cases Named
Under the court's trial selection protocol, plaintiffs and defendants each submitted eight cases, forming a pool of 16 early trial selection cases. In all 16, the parties waived remand and agreed to bellwether trials before Judge Rosenstengel in the MDL court itself.
Bellwether Protocol and First Trial Date Set
Case Management Order No. 12 explained how test cases would be chosen: plaintiffs picked eight, Chevron four, and Syngenta four for limited fact discovery. It set the first trial for Nov. 15, 2022, with more trials planned for March 13, June 12, and Sept. 18, 2023.
Chevron U.S.A. Confirmed as Proper Chevron Defendant
Chevron U.S.A. Inc. stated it had taken on the paraquat liabilities of the former Chevron Chemical Company. Case Management Order No. 11 then provided for dismissing, on Chevron's motion, claims against Chevron Phillips Chemical, Phillips 66, and Chevron Corporation, plus claims against Chevron U.S.A. alleging exposure that began in 1990 or later.
Plaintiff Questionnaire Rules Adopted
Case Management Order No. 10 set rules for the Plaintiff Assessment Questionnaire, a sworn early form describing each plaintiff's claim, served through an online portal run by Postlethwaite & Netterville. Plaintiffs who fail to serve it, or who file a seriously deficient one and do not fix it, face dismissal.
EPA Issues Interim Decision With New Limits
EPA published notice of its July 2021 interim registration review decision for paraquat. The decision added enforceable protections such as caps on aerial spraying, drift buffers near homes, and a ban on human flaggers. On its paraquat page, EPA states it has found no clear link between labeled paraquat use and Parkinson's disease.
Randi Ellis Named Special Master
Case Management Order No. 4 appointed Randi S. Ellis as special master, a court-appointed neutral who carries out duties the judge assigns in managing the litigation. Her fees are split evenly between plaintiffs' leadership and the defendants.
Plaintiffs' Leadership Appointed
After reviewing 80 applications and interviewing 41 lawyers, the court named the plaintiffs' leadership: co-lead counsel, liaison counsel for the MDL and state courts, and an executive committee to guide the litigation for all plaintiffs. The first appointments ran for one year.
Federal Paraquat MDL Created in Southern Illinois
The federal Judicial Panel on Multidistrict Litigation centralized federal paraquat cases alleging Parkinson's disease in Illinois' Southern District as MDL No. 3004, with Nancy J. Rosenstengel, the district's chief judge, presiding. The motion listed 14 actions in six districts. The panel noted that Illinois ranks in the top five states for paraquat use and that, according to plaintiffs' counsel, Illinois state court cases had been underway for several years.
Syngenta Agrees to $187.5 Million Settlement
Syngenta disclosed in its financial statements that it signed a master settlement agreement with certain paraquat claimants on June 1, 2021. In return for dismissal of all their counsel's pending cases and a broad release, it agreed to pay $187.5 million into a settlement fund, which it paid on July 21, 2021. Syngenta said the claims lacked merit and that it settled only to end them.
What Is the Paraquat Lawsuit?
Paraquat, a widely used herbicide (or weed killer), has come under intense scrutiny in recent years due to its association with Parkinson’s disease and other serious health risks. Paraquat has been a staple in agricultural practices since the 1960s. However, its high toxicity levels have led to mounting concerns and a wave of lawsuits aimed at holding manufacturers and distributors accountable for the harm allegedly caused by Paraquat exposure.
The Paraquat lawsuit has some similarities to the ongoing Roundup lawsuit. However, because Paraquat’s use is restricted, the Paraquat lawsuit has far fewer plaintiffs.
Since Paraquat's introduction into agricultural settings, many people were unknowingly exposed to Paraquat and were later diagnosed with Parkinson’s Disease or other long-term health issues. In some situations, a person may have been knowingly exposed to Paraquat but was not informed of the risks. The defendants in Paraquat lawsuits are primarily manufacturers such as Chevron, Syngenta, Adama, Helm and Drexel.
Since June 2021, lawsuits filed in federal court have been consolidated in MDL No. 3004 in the Southern District of Illinois before Chief Judge Rosenstengel. Since May 2022, Philadelphia’s Court of Common Pleas has accepted lawsuits from plaintiffs across the country in a separate mass tort program.
Latest Updates on the Paraquat MDL
The Paraquat multidistrict litigation (MDL) has continued to grow over the past several months. These are some of the most important updates:
The Global Settlement Moves Forward
In May 2025, the judge paused bellwether discovery deadlines for 30 days after the lead lawyers on both sides reached a tentative settlement agreement. This stay temporarily halted these specific cases so the two sides could continue working on a settlement. The stay was extended several times, since negotiating lawsuit settlements in MDLs can be extremely difficult.
The judge ordered a final extension on December 30, 2025, delaying discovery deadlines to March 6, 2026. On March 2, 2026, the court approved a qualified settlement fund. This court-supervised account holds settlement money until it is paid out to claimants.
After seeing how much was offered, many plaintiffs declined to settle their cases. The declining parties included every DiCello Levitt client and more than 90% of Smith Law Firm clients. Those who decline must now prove their cases in court to recover compensation.
Starting on November 5, 2026, the court plans to hold in-person status conferences in the remaining MDL cases every two weeks.
New Lawsuits Keep Coming
Plaintiffs continue to file new cases despite settlement talks. The Paraquat MDL had 6,635 pending cases on November 2, 2026.
However, it’s important to note that even though the total case count is growing, weaker claims or those without evidence are also being dismissed. For those with strong, evidence-backed claims, weeding out unsubstantiated claims can increase the chances of a fair settlement.
Past Paraquat Lawsuit Updates
Late in January 2025, a Wisconsin man filed a lawsuit alleging his prolonged exposure to Paraquat caused his Parkinson’s disease. The lawsuit is filed as part of the Paraquat MDL.
The plaintiff states that his exposure to Paraquat occurred during his work as an agronomist from 1980 to 1985. The lawsuit alleges that Paraquat is unreasonably dangerous and defectively designed. It also asserts that the manufacturer failed to warn users of Paraquat’s neurotoxic risks, a pattern echoed in ultra-processed food lawsuits, where companies are accused of concealing links to conditions like diabetes and liver disease.
Another MDL Paraquat lawsuit was filed in Florida at the end of January. A Florida man alleges that Paraquat exposure caused his Parkinson’s disease, which was diagnosed in 2020. The complaint details that the plaintiff was regularly exposed to Paraquat while maintaining a property from 2013 to 2019.
The plaintiff and his spouse, who has joined the lawsuit, are pursuing compensation for healthcare expenses, pain and suffering, loss of companionship and other damages.
California Cancels All Paraquat Products
According to Assembly Bill 1963, signed by Gov. Gavin Newsom in 2024, the California Department of Pesticide Regulation (DPR) must complete a reevaluation of the pesticide paraquat by January 2029. On December 30, 2024, the DPR released two preliminary scientific reports on human health effects and the ecotoxicology of Paraquat.
While the DPR did not find a causal association between Paraquat exposure and Parkinson’s disease, the studies identified an association between birth defects and thyroid impacts and exposure to Paraquat. However, a study published by the National Library of Medicine earlier in 2024 did establish a link between exposure to Paraquat and Parkinson’s disease.
By August 6, 2026, every Paraquat manufacturer voluntarily gave up state registration. On August 10, 2026, the DPR announced that all Paraquat products in California were canceled. Licensed dealers can possess and sell canceled products for up to two years after a cancellation takes effect, however.
Status of the Paraquat Bellwether Trial
Paraquat victims have yet to get their day in court. In April 2024, the MDL judge excluded the plaintiffs’ expert witness on general causation and dismissed four bellwether trial cases. The court then set other cases for bellwether trials on October 14, 2025, and April 6, 2026. Both of these trial dates were canceled as settlement talks continued. An appeal of the earlier dismissals was also delayed.
Cases that were not dismissed or delayed were settled by the defendants to avoid the uncertainties and costs of an unfavorable and potentially precedential result. In April 2025, the parties reached a tentative agreement to settle one of the bellwether cases.
Another bellwether trial scheduled for January 2026 was canceled when the parties settled on the eve of trial.
A New York Times Article Reveals Unsettling Truths
In many lawsuits involving dangerous drugs, it often eventually comes to light that the manufacturer knew about the risks and suppressed information to protect profits. This appears to be the case with Paraquat as well.
A New York Times article released in September 2025 revealed evidence that manufacturers have been aware of Paraquat’s detrimental effects on the nervous system for years. Those manufacturers deliberately downplayed the risks while continuing to promote the herbicide.
Importantly, the article pointed out that Paraquat and other herbicides aren’t just responsible for a small portion of cases. Many scientists have come to believe that Parkinson’s disease is largely caused by human-made environmental toxins.
Regulators in many other countries have banned Paraquat because of its extreme toxicity to humans. Even if the Paraquat MDL doesn’t lead to the herbicide being banned, it can at least hold manufacturers accountable for the harm they’ve caused.
What Is Paraquat?
Paraquat, developed primarily by Syngenta and Chevron and manufactured by several companies nationally and abroad, is a highly effective herbicide primarily used to control weeds and unwanted vegetation in agricultural settings. Its fast-acting nature and broad-spectrum control make it a popular choice among farmers and agricultural workers worldwide. Paraquat works by disrupting photosynthesis in plants upon contact, effectively killing them within days of application.
Despite its effectiveness, Paraquat is classified as a restricted-use pesticide in the United States due to its high toxicity. It is only available to certified applicators who have undergone specific training on handling and application procedures to minimize risks.
Who Manufactures Paraquat and Where Is It Used?
Paraquat is mostly used in farms to control weed growth. There are almost 400 countries around the world that manufacture products containing Paraquat. However, it’s not as ubiquitous as that statistic makes it seem. At least 32 countries have banned Paraquat outright because of how dangerous it is to human health.
In the United States, Syngenta is the main distributor of Paraquat. Chevron Chemical Company manufactured the chemical for two years before stopping in 1986. However, it didn’t stop making Paraquat because it realized how dangerous the chemical was — the market just became so competitive that manufacturing it was no longer profitable.
Syngenta is now leaving the market, too. In March 2026, it announced it would stop making paraquat due to generic competition. Syngenta planned to cease production at its Huddersfield, U.K., plant by late June 2026.
Symptoms and Health Risks of Paraquat Exposure
The controversy surrounding Paraquat stems from its potential health hazards, particularly upon human exposure. The herbicide is known to be highly toxic, with even small amounts posing significant risks to human health. Paraquat poisoning can occur through inhalation, ingestion or skin contact, with symptoms ranging from mild irritation to severe poisoning and even death.
Acute Paraquat poisoning can lead to a range of symptoms, including nausea, vomiting, abdominal pain, difficulty breathing and organ failure. Ingestion of even a small amount of Paraquat can be fatal, making it a highly dangerous substance.
Most notably, studies have suggested a potential link between Paraquat exposure and the development of Parkinson's disease. Research conducted on both animals and humans has found correlations between Paraquat exposure and an increased risk of developing Parkinson's, a progressive neurodegenerative disorder characterized by motor impairment and cognitive decline. As a result, Paraquat has been banned in dozens of countries worldwide in the last few years, including the EU and China, and several lawsuits (both class-action and individual) have been filed in the U.S., where Paraquat is still used outside California.
How to Qualify for a Paraquat Lawsuit
Individuals who have been adversely affected by Paraquat exposure, either through direct contact or environmental exposure, may be eligible to file a claim against the manufacturers and distributors of Paraquat-based herbicides. These include the following:
- Farmers
- Agricultural workers
- Pesticide applicators
- Individuals working in Paraquat manufacturing plants
- People who live near areas where Paraquat is used
Litigation will be primarily looking at the connection between negligent application of Paraquat and the development or risk of Parkinson’s and other certain diseases. To maximize your chances of success, you should ensure your product liability attorney can prove the following:
- You were exposed to Paraquat
- You suffered serious health problems
- Your exposure to Paraquat caused those health problems
Plaintiffs who decline their individualized offers, don’t qualify for the global settlement or filed after the deadline must meet the proof rules in Case Management Order No. 25. These requirements include:
- Sworn fact sheet
- Proof of paraquat use
- Witness affidavits
- Parkinson’s diagnosis from a movement disorder specialist or neurologist made at least 10 years after first use
- Case-specific causation expert report
The court can dismiss with prejudice cases that fail to comply.
The Paraquat lawsuits not only provide an opportunity for plaintiffs to claim well-deserved compensation, but they also highlight the growing awareness and concern surrounding the health risks associated with agricultural chemicals and the need for stricter regulation and oversight in their use. As more evidence emerges linking Paraquat exposure to adverse health outcomes, the pressure on manufacturers and regulatory agencies to address these concerns continues to mount.
Paraquat Lawsuit Settlements & Payouts
Paraquat exposure can result in long-lasting and invasive symptoms. If you’ve been diagnosed with Parkinson’s Disease or another condition as a result of Paraquat exposure, you may be entitled to significant damages as a result of the suffering you’ve endured.
In June 2021, Syngenta agreed to pay $187.5 million into a settlement fund to resolve certain claimants' cases. Starting in April 2025, the lead attorneys for both parties began discussing a global MDL settlement. On March 2, 2026, the court created a qualified settlement fund to offer payouts to eligible claimants based on an assigned settlement tier.
How Much Can You Get From the Paraquat Lawsuit?
The global Paraquat settlement is private and confidential. The claims administrator creates an individualized offer for each claimant by assigning a settlement tier. However, there are no confirmed public documents explaining these tiers.
Claimants can accept or decline their individualized offers. But claimants who decline generally will not receive any compensation unless they prove their case in court. A toxic tort lawyer can help Paraquat victims prepare a claim and evaluate whether the claims administrator’s offer reflects their suffering and financial losses.
Legal and Financial Options for Paraquat Victims
Filing a Paraquat lawsuit is about holding negligent manufacturers accountable, but it’s also about ensuring you get the compensation you need to heal and move on with your life. Your lawyer may be able to help you sue for compensation for losses. There are two main types.
- Non-Economic Damages: Compensation for pain and suffering and other intangible losses
- Economic Damages: Compensation for lost wages and other losses you can quantify
Factors That Determine Paraquat Settlement Amounts
There are several factors that could either increase or decrease the amount an individual may earn in a settlement against Paraquat manufacturing companies and applicators acting in negligence. The litigation will be looking at the following factors:
Extent of Injury or Illness
The severity of the plaintiff's illness or injury is a significant factor in determining settlement amounts. Plaintiffs who have suffered more severe health effects, such as Parkinson's disease or other debilitating conditions, may be entitled to higher settlements to compensate for medical expenses, lost wages, pain and suffering and other damages.
Medical Expenses
Plaintiffs may receive compensation for past and future medical expenses related to their illness or injury. This can include costs for doctor visits, hospitalizations, medications, rehabilitation therapy and other medical treatments necessitated by Paraquat exposure.
Lost Wages and Future Earning Capacity
If Paraquat exposure has caused the plaintiff to miss work or if it is expected to impact their ability to work in the future, they may be entitled to compensation for lost wages and diminished earning capacity.
Pain and Suffering
Plaintiffs may receive compensation for physical pain, emotional suffering and mental anguish caused by their illness or injury. The amount awarded for pain and suffering is often subjective and may vary based on the specific circumstances of the case.
Proving Paraquat Exposure and Building a Case
Depending on your situation, proving exposure might be simple — but it also might not be. For instance, if you’re a former agricultural worker, tax forms or other employment records could be used as proof. However, if you worked on a farm where you were paid in cash, proving Paraquat exposure could be much harder.
The court requires evidence to support legal claims. Thus, every MDL plaintiff must serve third-party subpoenas for records proving Paraquat use or exposure within 60 days of the court’s order or initial filing, whichever occurs first.
Regardless of your situation, you should reach out to an attorney as soon as you can. The right lawyer will understand how to prove exposure and maximize your chances of a fair Paraquat settlement.
Paraquat Lawsuit Knowledge Base
No topics match your search.
Frequently Asked Questions
The time for the onset of symptoms after paraquat exposure can vary widely. The MDL court requires a Parkinson’s diagnosis obtained at least 10 years after first paraquat use in all federal cases that fall outside the global settlement.
Paraquat is generally an herbicide for farms and agricultural settings. It is not often used for the maintenance of residential gardens and yards.
Yes, Parkinson's disorder can also be caused by other factors like genetic variation, age, and environmental toxin exposure. However, paraquat is more likely to increase the risk of developing Parkinson's disorder in oneself. Therefore, it's crucial to consider some other factors that may cause this disease in the members of a family.
Until now, Parkinson's disease does not have a cure. However, several medications and treatments have been introduced to control and lessen the symptoms, enhancing life expectancy and decreasing the development of the ailment in some scenarios.
Paraquat has neurotoxic effects, including the development of oxidative stress and ROS. This leads to brain cell damage. However, the exact way paraquat impacts the brain is quite complex and is still under investigation.
Resources
Explore related articles and sources cited on this page.